As a doctor, or patient, you may be confused about the current status of cannabis-based medicinal products (CBMPs). On the 8th of August 2019, the National Institute for Health and Care Excellence (NICE) published draft guidance in respect of CBMPs, and how it is envisaged they should be used.
To clarify, at present, Sativex and Nabilone are the only CBMPs licensed for use in adults in the United Kingdom (UK). The medicines are listed under Schedule 4 and Schedule 2 of the Misuse of Drugs Regulations 2001 respectively.
The guidelines cover ‘prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy’, and are proposed for publication in November 2019.
The recommendations are broadly that:
- Nabilone should be considered as an